In vivo electroporation of a new gene vaccine encoding ten repeats of aβ3-10 prevents brain aβ deposition and delays cognitive impairment in Young Tg-APPswe/PSEN1dE9 Mice

Neurochemical Research

Volumn 37, Issue 7, 2012, Pages 1534-1544

  Sha, Sha ^a   Xing, Xiao Na ^a   Guo, Wan Shu ^a   Li, Yu ^a   Zong, Li Xia ^a   Guo, Rong ^b   Cao, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b People's Hospital of Liaoning Province   (China)

Author keywords

Alzheimer's disease; Amyloid b protein In vivo electroporation; Gene vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[3-10]; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; INTERLEUKIN 4; MELATONIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BRAIN LEVEL; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; EX VIVO STUDY; GLIA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH2 CELL;

AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; CYTOKINES; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINES, DNA;

MUS;

EID: 84862855116     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0748-7     Document Type: Article

References (41)

1. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
3. Dodart JC, Bales KR, Gannon KS et al (2002) Immunization reduces memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457
4. Rosenberg RN (2005) Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol 62:1506-1507
5. Ferrer I, Boada Rovira M, Sánchez Guerra ML et al (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20
6. Patton RL, Kalback WM, Esh CL et al (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169:1048-1063
7. Cribbs DH (2010) Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord: Drug Targets 9:207-216
8. Wiessner C, Wiederhold KH, Tissot AC et al (2011) The secondgeneration active A{beta} immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31:9323-9331
9. Qu B, Rosenberg RN, Li L et al (2004) Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 61:1859-1864
10. Qu BX, Xiang Q, Li L et al (2007) Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 260:204-213
11. Agadjanyan MG, Ghochikyan A, Petrushina I et al (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174:1580-1586
12. Ghochikyan A, Mkrtichyan M, Petrushina I et al (2006) Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Ab antibody response with Alum to Quil A adjuvant switch. Vaccine 24:2275-2282
13. Monsonego A, Maron R, Zota V et al (2001) Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A 98:10273-10278
14. Seabrook TJ, Thomas K, Jiang L et al (2007) Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 28:813-823
15. McLaurin J, Cecal R, Kierstead ME et al (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloidbeta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-1269
16. Moretto N, Bolchi A, Rivetti C et al (2007) Conformationsensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 282:11436-11445
17. Frenkel D, Kariv N, Solomon B (2001) Generation of autoantibodies towards Alzheimer's disease vaccination. Vaccine 19:2615-2619
18. Zou J, Yao Z, Zhang G et al (2008) Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Ab1-15 reduces Ab burden and behavioral impairment without Ab-specific T cell response. J Neurol Sci 272:87-98
19. Donnelly JJ, Liu MA, Ulmer JB (2000) Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 162:S190-S193
20. Boyer JL, Kobinger G, Wilson JM et al (2005) Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 16:157-168
21. Kim HD, Kong FK, Cao Y et al (2004) Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 370:218-223
22. Zhang J, Wu X, Qin C et al (2003) A novel recombinant adenoassociated virus vaccine reduces behavioral impairment and bamyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14:365-379
23. Otten G, Schaefer M, Doe B et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489-2493
24. Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16:867-870
25. Schenk D, Barbour R, Dunn W (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177
26. Wang CY, Wang T, Zheng W et al (2010) Zinc overload enhances APP cleavage and Ab deposition in the Alzheimer mouse brain. PLoS ONE 5:e15349
27. Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223
28. St. George-Hyslop PH, Morris JC (2008) Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372:180-182
29. Finocchiaro LM, Nahmod VE, Launay JM (1991) Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 280:727-731
30. Hellstrand K, Hermodsson S (1990) Monocyte-mediated suppression of IL-2-induced NK-cell activation: regulation by 5-HT1-type serotonin receptors. Scand J Immunol 32:183-192
31. Shaji AV, Kulkarni SK, Agrewala JN (1998) Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin Exp Immunol 111:181-185
32. Reiter RJ, Cabrera J, Sainz RM et al (1999) Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann NY Acad Sci 890:471-485
33. Connor TP (2008) Melatonin as an adjuvant to therapeutic prostate cancer vaccines. J Pineal Res 45:224
34. Lambracht-Washington D, Qu BX, Fu M et al (2009) DNA betaamyloid( 1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 302:1796-1802
35. Torres KC, Dutra WO, Gollob KJ (2004) Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4? T helper cells. Hum Immunol 65:1328-1335
36. Wang YJ, Pollard A, Zhong JH et al (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30:364-376
37. Janus C, Pearson J, McLaurin J et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982
38. Wilcock DM, Munireddy SK, Rosenthal A et al (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15: 11-20
39. DeMattos RB, Bales KR, Cummins DJ et al (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850-8855
40. Solomon B, Koppel R, Frankel D et al (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94:4109-4112
41. Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36:180-190